Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
1. A method for treatment pulmonary hypertension, comprising administering to a subject suffering from pulmonary hypertension (i) a first prostacyclin and (ii) mesenchymal stem cells (MSCs), wherein the MSCs have been contacted with a second prostacyclin prior to administration.
2. The method of claim 1 , wherein the first and second prostacyclin are the same prostacyclin.
3. The method of claim 1 , wherein the first or second prostacyclin is treprostinil.
4. The method of claim 1 , wherein the first prostacyclin and MSCs are co-administered.
5. The method of claim 1 , wherein the first prostacyclin is administered before the MSCs are administered.
6. The method of claim 1 , wherein the first prostacyclin is administered after the MSCs are administered.
7. The method of claim 1 , wherein the MSCs are contacted with the second prostacyclin ex vivo.
8. The method of claim 7 , wherein the MSCs are contacted with a growth factor ex vivo.
9. The method of claim 1 , wherein the MSCs are obtained from the subject.
10. The method of claim 1 , wherein the patient is suffering from pulmonary arterial hypertension.